Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer

被引：72
|
作者：
De Giorgi, U. [1 ,2 ,3 ]
Valero, V. [1 ]
Rohren, E. [4 ]
Mego, M. [1 ,2 ]
Doyle, G. V. [5 ]
Miller, M. C. [5 ]
Ueno, N. T. [1 ,6 ]
Handy, B. C. [7 ]
Reuben, J. M. [2 ]
Macapinlac, H. A. [4 ]
Hortobagyi, G. N. [1 ]
Cristofanilli, M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[3] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA
[5] Immunicon Corp, Huntingdon Valley, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷 / 01期
关键词：
bone metastases; breast cancer; circulating tumor cells; FDG-PET; CT; prognosis; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; CARCINOMA; THERAPY; CHEMOTHERAPY; EXPRESSION; RESISTANCE; PROGNOSIS; SURVIVAL; DISEASE; BURDEN;
D O I：
10.1093/annonc/mdp262
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients and methods: From May 2004 to January 2008, 195 patients with relapsed/progressive MBC underwent whole-body FDG-PET/CT and provided blood samples for assessment of CTC count. Results: Higher CTC numbers were detected in patients with bone metastases relative to those with no bone lesions (mean 65.7 versus 3.3, P = 0.0122) and in patients with multiple bone metastases relative to those with one or two bone lesions (mean 77.7 versus 2.6, P < 0.001). CTCs predicted overall survival (OS) in 108 patients with multiple sites of metastases including bone (P = 0.0008) but not in 58 without bone metastases (P = 0.4111) and in 29 with bone involvement only (P = 0.3552). All 15 patients but one with human epidermal growth factor receptor 2 (HER-2) positive tumors who were treated with trastuzumab-based regimens had < 5 CTCs at progression. In multivariate analysis, CTCs, but not bone metastases, remained a significant predictor of OS. Conclusion: Presence of extensive bone metastases as detected by FDG-PET/CT is associated with increased CTC numbers in MBC.
引用
收藏
页码：33 / 39
页数：7
相关论文
共 50 条
  • [21] Preoperative FDG-PET for axillary metastases in patients with breast cancer - Discussion
    Giuliano, Armando E.
    Silberman, Howard
    Vetto, John T.
    Wagman, Lawrence D.
    Pommier, Rodney F.
    [J]. ARCHIVES OF SURGERY, 2006, 141 (08) : 788 - 789
  • [22] Overlooked Unusual Left Ventricle Metastases Detected On FDG-PET/CT
    Lu, Yang
    [J]. INTERNAL MEDICINE, 2016, 55 (12) : 1673 - 1674
  • [23] Diagnostic accuracy of FDG-PET/CT and ultrasound for the detection of lymph node metastases in breast cancer patients
    Heusner, T. A.
    Koeninger, A.
    Kuemmel, S.
    Bockisch, A.
    Forsting, M.
    Antoch, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S275 - S275
  • [24] [18F]FDG-PET/CT patterns of bone metastases in lung cancer
    Perri, M.
    Volterrani, D.
    Erba, P.
    Lucchi, M.
    Mattone, V.
    Rizza, E.
    Pesella, F.
    Mariani, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S287 - S288
  • [25] Recurrent and metastatic head and neck cancer detected by FDG-PET in comparison to CT or MRI.
    Yu, JQ
    Kumar, R
    Zhuang, HM
    Sewell, DA
    Chalian, A
    Weber, R
    Weinstein, G
    Alavi, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S326 - S326
  • [26] Splenic and multiple abdominal metastases of endometrial carcinoma detected with FDG-PET/CT
    Kara, T.
    Kara, P. O.
    Gedik, G. K.
    Sari, O.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2012, 31 (01): : 31 - 33
  • [27] Whole body PET(CT) with FDG for treatment monitoring of patients with bone metastatic breast cancer
    Huyge, V.
    Flamen, P.
    Bergmann, P.
    Ameye, L.
    Vanderlinden, B.
    Garcia, C.
    Alexiou, J.
    Lemort, M.
    Awada, A.
    Body, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Assessment of hormonal therapy response using FDG-PET/CT in metastatic breast cancer
    Mortazavi-Jehanno, N.
    Giraudet, A. L.
    Edeline, V.
    Banayan, S.
    Madar, O.
    Tubiana, M.
    Pecking, A. P.
    Alberini, J. L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S176 - S176
  • [29] Breast cancer: treatment response assessment with FDG-PET/CT in the neoadjuvant and in the metastatic setting
    David Groheux
    Gary A. Ulaner
    Elif Hindie
    [J]. Clinical and Translational Imaging, 2023, 11 : 439 - 452
  • [30] Breast cancer: treatment response assessment with FDG-PET/CT in the neoadjuvant and in the metastatic setting
    Groheux, David
    Ulaner, Gary A.
    Hindie, Elif
    [J]. CLINICAL AND TRANSLATIONAL IMAGING, 2023, 11 (05) : 439 - 452
12345